DANANG-CVT
A Prospective Registry of Patients With Cerebral Venous Thrombosis at Da Nang Hospital: Clinical Characteristics, Imaging Manifestations, and Functional Outcomes
Sponsor study identifier
observational
110
1 country
1
Study Start
October 9, 2025
Actual (reported)Primary Completion
October 9, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Cerebral venous thrombosis (CVT) is an uncommon but potentially life-threatening type of stroke, predominantly affecting young adults and women. Although prompt diagnosis and anticoagulant therapy can lead to favorable outcomes, data regarding the clinical spectrum, neuroimaging patterns, risk factors, and long-term functional recovery of CVT patients in central Vietnam remain limited. This prospective observational study aims to establish a hospital-based registry to investigate the clinical characteristics, neuroimaging features, etiology, and treatment outcomes of patients diagnosed with cerebral venous thrombosis at Danang Hospital. All consecutive patients with confirmed CVT admitted to Danang Hospital are enrolled and managed according to standard clinical protocols. Participants are monitored throughout their hospital stay to assess acute manifestations, imaging abnormalities on computed tomography (CT), computed tomography venography (CTV), magnetic resonance imaging (MRI), or magnetic resonance venography (MRV), and inpatient complications. Functional outcomes and recovery are evaluated at hospital discharge and during follow-up using the modified Rankin Scale (mRS).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 9, 2025
Actual (reported)October 16, 2026
Actual (reported)October 22, 2026
Actual (reported)October 9, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Favorable Functional Outcome Assessed by the Modified Rankin Scale (mRS)
Functional status is evaluated using the modified Rankin Scale (mRS), a standardized clinical tool measuring the degree of disability or dependence in daily activities. The scale ranges from 0 (no symptoms) to 6 (death). A favorable functional outcome is defined as an mRS score of 0 to 1 (complete recovery or no significant disability despite symptoms)
At 6 months post-diagnosis
Venous Recanalization Rate at 6 Months
At 6 months post-diagnosis
All-Cause Mortality at 6 Months
At 6 months post-diagnosis
All consecutive adult patients diagnosed with cerebral venous thrombosis (confirmed by CTV or MRV) admitted to Danang Hospital and followed up for clinical characteristics, neuroimaging features, and functional outcomes.
Patients receive therapeutic anticoagulation according to standard clinical guidelines (low-molecular-weight heparin or unfractionated heparin in the acute phase, followed by oral anticoagulants including vitamin K antagonists or direct oral anticoagulants), along with supportive medical care and endovascular treatment when indicated.
All consecutive adult patients (aged 18 years or older) diagnosed with cerebral venous thrombosis (CVT) admitted to the Stroke and Neurointensive Care Department at Danang Hospital. The diagnosis of CVT must be objectively confirmed by definitive neuroimaging, including magnetic resonance venography (MRV), computed tomography venography (CTV), or digital subtraction angiography (DSA). Patients are enrolled irrespective of clinical presentation (acute, subacute, or chronic onset) and are managed according to standard clinical protocols.
Da Nang Hospital
Da Nang, Da Nang, 50000, Vietnam
Son V. D. Nguyen, MD, MSc
Da Nang Hospital
First Submitted
October 16, 2026
First Posted
October 22, 2026
Study Start
October 9, 2025
Actual (reported)Primary Completion
October 9, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis
Health-Related Quality of Life Assessed by the EuroQol 5-Dimension (EQ-5D-5L) Questionnaire
At 6 months post-diagnosis
Contact the study team to confirm eligibility.
Study Completion
July 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 26, 2026
Record last verified: 2026-10
Individual participant data will not be made publicly available due to patient confidentiality and institutional data governance policies. However, de-identified data may be considered for sharing with qualified researchers upon reasonable scientific request to the corresponding author, subject to formal approval by the Institutional Review Board of Danang Hospital.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: